קיוביצין 500 מ"ג - Cubicin 500 mg
ש××× ×× !
×ת×ר××: 02/12/2024 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 02/12/2024 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
××§×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש××××§ תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | J01XX Other antibacterials |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V
×××§× ××××שת ××קפ×× ×××× ×ª ת×××¡× ×××רק×, LYOPHILIZED POWDER FOR SOLUTION FOR INJECTION |
| ×ת×××× | Cubicin is indicated for the treatment of the infections listed below. * Complicated Skin and Skin Structure InfectionsComplicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).* Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant IsolatesStaphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.* Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram negative or anaerobic organisms
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ×§××××צ×× 500 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | MERCK SHARP & DOHME CORP., USA |
| ×©× ××¢× ×ר×ש×× | MERCK SHARP & DOHME ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 02/2014. ר×ש××× ×ת×ר××: 06/2014 |
| ת×ר×× ×¢×××× ××ר×× | 02/12/2024 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־8 בפברואר 2025 ב־20:02